XNAS
JUNO
, Last price
USD
Name
Juno Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
112m
+40.97%
Net income
-437m
L+77.99%
CFO
-225m
L+18.56%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Key people
President of Research & Development · since 2017
President, Chief Executive Officer · since 2018
Chief Financial Officer, Head of Corporate Development · since 2014
Ann Louise Lee
Executive Vice President - Technical Operations · since 2017
Executive Vice President · since 2017
Executive vice president - Research, chief scientific officer · since 2015
Bernard J. Cassidy
General Counsel, Secretary · since 2014
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
400 Dexter Avenue North
Suite 1200
Seattle, WA 98109
US
Suite 1200
Seattle, WA 98109
US
Valuation
Title in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2017‑12 | 2016‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT |